The European Parliament and the Council have introduced the possibility of building up a stock of generics from 6 months before the end of the supplementary protection certificate (SPC) for medicinal products, following an agreement sealed at an interinstitutional meeting on Thursday 14 February.
This means that a drug manufacturer will be able to build up a stock of marketable generics 6 months before the end of the certificate's validity - a proposal that had been made by the European...